The Johnson & Johnson filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of...
Vous n'êtes pas connecté
The FDA bestows a Breakthrough Therapy Designation to GSK's B7-H3-targeted antibody-drug conjugate, GSK5764227, for relapsed/refractory extensive-stage small-cell lung cancer.
The Johnson & Johnson filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of...
CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell...
Exosome-based therapy targets squamous cell carcinomas that are drug-resistant and offers new hope for patients with drug-resistant cancers
Exosome-based therapy targets squamous cell carcinomas that are drug-resistant and offers new hope for patients with drug-resistant cancers
Illumina's cancer biomarker test, TSO Comprehensive, gets approved by the FDA for use as CDx to match patients with targeted therapies.
Data from a late-stage study shows that SMMT's experimental antibody beat Keytruda in a head-to-head setting in treating certain patients with NSCLC.
Iterum provides updates from the FDA's Antimicrobial Drugs Advisory Committee meeting on its NDA for oral sulopenem to treat adult women with uUTI.
BASKING RIDGE, N.J. & RAHWAY, N.J., September 7, 2024 – Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01...
BASKING RIDGE, N.J. & RAHWAY, N.J., September 7, 2024 – Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01...
The FDA accepts and grants priority review to SpringWorks' NDA for mirdametinib for treating neurofibromatosis type 1-associated plexiform...